RELAPSED / REFRACTORY AML
Clinical trials for RELAPSED / REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED / REFRACTORY AML trials appear
Sign up with your email to follow new studies for RELAPSED / REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Weekly pill cocktail aims to tame resistant blood cancers
Disease control Not yet recruitingThis phase 2 trial tests whether a once-weekly oral combination of decitabine-cedazuridine and venetoclax is safer and as effective as standard therapy for people with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk myeloproliferati…
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Donor cells take on tough leukemia in new trial
Disease control Not yet recruitingThis study tests a new treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially modified immune cells from a healthy donor to attack the cancer. The first part finds the safest dose, and the second part checks how well i…
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC